New Ray Medicine International Holding (HKSE:06108) Moat Score: 0/10 (As of Aug. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06108 New Ray Medicine International Holding Ltd HKSE:06108
52 GF Score
Price HK$0.23
GF Value HK$1.04
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is New Ray Medicine International Holding Moat Score?

New Ray Medicine International Holding has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

New Ray Medicine International Holding has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes New Ray Medicine International Holding might have No Moat - No discernible moat.

New Ray Medicine International Holding  (HKSE:06108) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

New Ray Medicine International Holding Moat Score Related Terms

HKSE:06108
52GF Score
New Ray Medicine International Holding Ltd HKSE:06108
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is New Ray Medicine International Holding (HKSE:06108) Overvalued in 2026?

Based on GuruFocus' analysis, New Ray Medicine International Holding stock appears to be undervalued. The current stock price of HK$0.23 is trading 78.4% below its estimated GF Value™ of HK$1.04. GuruFocus considers New Ray Medicine International Holding to be Possible Value Trap.

Key valuation signals for HKSE:06108:

  • Moat Score: 0
  • GF Value™: HK$1.04 vs. price of HK$0.23 (78.4% below fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the HKSE:06108 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

New Ray Medicine International Holding Business Description

Address 19 Dangui Road, B-C, 37th Floor, Dikai International Center, Hangzhou, CHN
New Ray Medicine International Holding Ltd is engaged in the trading and distribution of pharmaceutical products in the People's Republic of China. The company's segments include the Distribution and trading of pharmaceutical products and the Provision of marketing and promotion services. Distribution and trading of pharmaceutical products segment consist of Injection drugs and generate maximum revenue for the company.
52GF Score

Get the complete analysis for HKSE:06108

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.23
Price
HK$1.04
GF Value